N
13.98
-0.02 (-0.14%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bullish | Bearish |
| Medical Devices (Global) | Bullish | Bearish | |
| Stock | Neuropace, Inc. | - | - |
|
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kck Ltd. | 30 Sep 2023 | 5,621,111 |
| Kent Lake Capital Llc | 31 Dec 2023 | 670,946 |
| 52 Weeks Range |
3.80 - 18.15
|
|
| Price Target Range | ||
| High | 20.00 (Wells Fargo, 43.06%) | Overweight |
| Median | 17.50 (25.18%) | |
| Low | 13.00 (Morgan Stanley, -7.01%) | Equal Weight |
| Average | 17.00 (21.60%) | |
| Total | 1 Equal Weight, 3 Overweight | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 14 Mar 2024 | 20.00 (43.06%) | Overweight | 13.63 |
| 22 Feb 2024 | 16.00 (14.45%) | Equal Weight | 15.31 | |
| JP Morgan | 12 Mar 2024 | 17.00 (21.60%) | Overweight | 13.67 |
| Cantor Fitzgerald | 06 Mar 2024 | 18.00 (28.76%) | Overweight | 13.98 |
| Morgan Stanley | 06 Mar 2024 | 13.00 (-7.01%) | Equal Weight | 13.98 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | - | 13.89 | -66,434 | -929,145 |
| Aggregate Net Quantity | -66,434 | |||
| Aggregate Net Value ($) | -929,145 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.89 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 24 Apr 2024 | Sell (-) | 1,781 | 13.56 | 24,150 | |
| ORBIMED ADVISORS LLC | 23 Apr 2024 | Sell (-) | 21,791 | 14.01 | 305,292 | |
| ORBIMED ADVISORS LLC | 22 Apr 2024 | Sell (-) | 24,609 | 14.00 | 344,526 | |
| ORBIMED ADVISORS LLC | 19 Apr 2024 | Sell (-) | 18,253 | 13.98 | 255,177 |
| Date | Type | Details |
|---|---|---|
| 17 Apr 2024 | Announcement | NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 |
| 27 Mar 2024 | Announcement | NeuroPace to Present at the Needham 23rd Annual Healthcare Conference |
| 05 Mar 2024 | Announcement | NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million |
| 15 Feb 2024 | Announcement | NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |